{"id":"beacopp-escalated-q3-weeks","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Pulmonary toxicity"}]},"_chembl":{"chemblId":"CHEMBL4107976","moleculeType":"Small molecule","molecularWeight":"479.83"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BEACOPP escalated is an intensive polychemotherapy combination used primarily in Hodgkin lymphoma. The regimen delivers higher doses of cytotoxic agents compared to standard BEACOPP, targeting malignant lymphocytes through multiple mechanisms including DNA alkylation, topoisomerase inhibition, and mitotic disruption. The escalated dosing is administered every 3 weeks with hematopoietic stem cell support in some protocols.","oneSentence":"BEACOPP escalated is a multi-drug chemotherapy regimen that combines bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone at escalated doses to kill rapidly dividing cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:47.070Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hodgkin lymphoma, advanced stages (Phase 3 evaluation)"}]},"trialDetails":[{"nctId":"NCT00433433","phase":"PHASE3","title":"Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2006-10","conditions":"Lymphoma","enrollment":1952}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BEACOPP escalated q3 weeks","genericName":"BEACOPP escalated q3 weeks","companyName":"European Organisation for Research and Treatment of Cancer - EORTC","companyId":"european-organisation-for-research-and-treatment-of-cancer-eortc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BEACOPP escalated is a multi-drug chemotherapy regimen that combines bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone at escalated doses to kill rapidly dividing cancer cells. Used for Hodgkin lymphoma, advanced stages (Phase 3 evaluation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}